DNLI
Denali Therapeutics Inc.
Biotechnology
Market Cap$3.08B
5Y Perf.-29.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
DNLI vs ARVN
Revenue, margins, valuation, and 5-year total return — side by side.
ARVN
Arvinas, Inc.
Biotechnology
Market Cap$652M
5Y Perf.-69.4%
DNLI vs ARVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | DNLI | ARVN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $3.08B | $652M |
| Revenue (TTM) | $0.00 | $263M |
| Net Income (TTM) | $-513M | $-81M |
| Gross Margin | — | 99.5% |
| Operating Margin | — | -44.0% |
| Total Debt | $33M | $9M |
| Cash & Equiv. | $205M | $143M |
DNLI vs ARVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DNLI
ARVN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Denali Therapeutics… (DNLI) | 100 | 70.8 | -29.2% |
| Arvinas, Inc. (ARVN) | 100 | 30.6 | -69.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DNLI vs ARVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ARVN leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
DNLI
Denali Therapeutics Inc.
The Long-Run Compounder
DNLI is the clearest fit if your priority is long-term compounding.
- -8.1% 10Y total return vs ARVN's -36.5%
Best for: long-term compounding
ARVN
Arvinas, Inc.
The Income Pick
ARVN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.15
- Rev growth -0.3%, EPS growth 53.8%, 3Y rev CAGR 26.0%
- Lower volatility, beta 1.15, Low D/E 2.0%, current ratio 4.92x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARVN | -0.3% revenue growth vs DNLI's -20.3% |
| Stability / Safety | ARVN | Beta 1.15 vs DNLI's 1.82, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ARVN | +52.8% vs DNLI's +37.6% |
| Efficiency (ROA) | ARVN | -9.3% ROA vs DNLI's -44.8%, ROIC -22.4% vs -42.8% |
DNLI vs ARVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2020
FY 2025
DNLI vs ARVN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDNLILAGGINGARVN
ARVNArvinas, Inc.
2leads
DNLIDenali Therapeutics I…
2leads
6 Total Categories
CATEGORYLEADERvs ARVNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DNLI1/1
Valuation MetricsMultiples, price ratios, and targets
ARVN2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARVN7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DNLI5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DNLI leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ARVN and DNLI operate at a comparable scale, with $263M and $0 in trailing revenue.
| Metric | DNLIDenali Therapeuti… | ARVNArvinas, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $263M |
| EBITDAEarnings before interest/tax | -$544M | -$111M |
| Net IncomeAfter-tax profit | -$513M | -$81M |
| Free Cash FlowCash after capex | -$422M | -$276M |
| Gross MarginGross profit ÷ Revenue | — | +99.5% |
| Operating MarginEBIT ÷ Revenue | — | -44.0% |
| Net MarginNet income ÷ Revenue | — | -30.8% |
| FCF MarginFCF ÷ Revenue | — | -105.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -84.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -9.0% | -65.1% |
DNLI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ARVN leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | DNLIDenali Therapeuti… | ARVNArvinas, Inc. |
|---|---|---|
| Market CapShares × price | $3.1B | $652M |
| Enterprise ValueMkt cap + debt − cash | $2.9B | $517M |
| Trailing P/EPrice ÷ TTM EPS | -6.64x | -7.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.48x |
| Price / BookPrice ÷ Book value/share | 3.41x | 1.52x |
| Price / FCFMarket cap ÷ FCF | — | — |
ARVN leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ARVN leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
ARVN delivers a -14.3% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-51 for DNLI. ARVN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to DNLI's 0.03x. On the Piotroski fundamental quality scale (0–9), ARVN scores 4/9 vs DNLI's 3/9, reflecting mixed financial health.
| Metric | DNLIDenali Therapeuti… | ARVNArvinas, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -50.6% | -14.3% |
| ROA (TTM)Return on assets | -44.8% | -9.3% |
| ROICReturn on invested capital | -42.8% | -22.4% |
| ROCEReturn on capital employed | -47.9% | -16.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.02x |
| Net DebtTotal debt minus cash | -$173M | -$134M |
| Cash & Equiv.Liquid assets | $205M | $143M |
| Total DebtShort + long-term debt | $33M | $9M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
ARVN leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DNLI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DNLI five years ago would be worth $3,630 today (with dividends reinvested), compared to $1,601 for ARVN. Over the past 12 months, ARVN leads with a +52.8% total return vs DNLI's +37.6%. The 3-year compound annual growth rate (CAGR) favors DNLI at -9.5% vs ARVN's -25.5% — a key indicator of consistent wealth creation.
| Metric | DNLIDenali Therapeuti… | ARVNArvinas, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +21.1% | -11.2% |
| 1-Year ReturnPast 12 months | +37.6% | +52.8% |
| 3-Year ReturnCumulative with dividends | -25.8% | -58.7% |
| 5-Year ReturnCumulative with dividends | -63.7% | -84.0% |
| 10-Year ReturnCumulative with dividends | -8.1% | -36.5% |
| CAGR (3Y)Annualised 3-year return | -9.5% | -25.5% |
DNLI leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — DNLI and ARVN each lead in 1 of 2 comparable metrics.
Risk & Volatility
ARVN is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than DNLI's 1.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DNLI currently trades 82.9% from its 52-week high vs ARVN's 70.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DNLIDenali Therapeuti… | ARVNArvinas, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.82x | 1.15x |
| 52-Week HighHighest price in past year | $23.77 | $14.51 |
| 52-Week LowLowest price in past year | $12.58 | $5.90 |
| % of 52W HighCurrent price vs 52-week peak | +82.9% | +70.2% |
| RSI (14)Momentum oscillator 0–100 | 54.8 | 42.6 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 808K |
Evenly matched — DNLI and ARVN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates DNLI as "Buy" and ARVN as "Buy". Consensus price targets imply 75.0% upside for DNLI (target: $35) vs 27.6% for ARVN (target: $13).
| Metric | DNLIDenali Therapeuti… | ARVNArvinas, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $34.50 | $13.00 |
| # AnalystsCovering analysts | 18 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +14.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
DNLI leads in 2 of 6 categories (Income & Cash Flow, Total Returns). ARVN leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Best OverallDenali Therapeutics Inc. (DNLI)Leads 2 of 6 categories
Loading custom metrics...
DNLI vs ARVN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DNLI or ARVN a better buy right now?
Analysts rate Denali Therapeutics Inc.
(DNLI) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DNLI or ARVN?
Over the past 5 years, Denali Therapeutics Inc.
(DNLI) delivered a total return of -63. 7%, compared to -84. 0% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: DNLI returned -8. 1% versus ARVN's -36. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DNLI or ARVN?
By beta (market sensitivity over 5 years), Arvinas, Inc.
(ARVN) is the lower-risk stock at 1. 15β versus Denali Therapeutics Inc. 's 1. 82β — meaning DNLI is approximately 59% more volatile than ARVN relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 3% for Denali Therapeutics Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — DNLI or ARVN?
On earnings-per-share growth, the picture is similar: Arvinas, Inc.
grew EPS 53. 8% year-over-year, compared to -15. 6% for Denali Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DNLI or ARVN?
Denali Therapeutics Inc.
(DNLI) is the more profitable company, earning 0. 0% net margin versus -30. 8% for Arvinas, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DNLI leads at 0. 0% versus -43. 8% for ARVN. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DNLI or ARVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DNLI or ARVN better for a retirement portfolio?
For long-horizon retirement investors, Arvinas, Inc.
(ARVN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15)). Denali Therapeutics Inc. (DNLI) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ARVN: -36. 5%, DNLI: -8. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DNLI and ARVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.